Transformers & Rectifiers (India) Limited has announced the resignation of Mr. Mukul Srivastava from his position as Chief Executive Officer (CEO), effective from the close of business hours on January 7, 2026. The resignation was communicated to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

The company filed the resignation intimation on January 8, 2026, citing personal circumstances as the reason for Mr. Srivastava's departure. The formal communication was addressed to both BSE Limited and National Stock Exchange of India Limited as part of regulatory compliance requirements.

Regulatory Communication

The resignation letter, dated November 18, 2025, was submitted to the Managing Director of Transformers and Rectifiers (India) Limited. In his resignation communication, Mr. Srivastava requested to be relieved of his duties by the end of January 7, 2026, and sought acknowledgment along with a relieving letter from the company.

Company Information

Transformers and Rectifiers (India) Limited operates in the Capital Goods - Electrical Equipment sector and is listed on both BSE (Security Code: 532928) and NSE (Trading Symbol: TARIL). The company's registered office is located at Survey No. 427 P/3-4 and 431 P/1-2, Sarkhej Bavla Highway, Village: Moraiya, Taluka: Sanand, Ahmedabad.

The resignation intimation was signed by Company Secretary Rakesh Kiri and digitally submitted to the stock exchanges as part of the company's disclosure obligations to keep investors informed about key management changes.

Cipla Limited has issued a clarification regarding USFDA inspectional observations on its supply partner Pharmathen International S.A., following media reports about regulatory concerns at the Greek manufacturing facility.

USFDA Inspection Details

The US Food and Drug Administration conducted an inspection at Pharmathen's manufacturing facility in Rodopi, Greece. The inspection resulted in nine inspectional observations being issued to the company.

Cipla's Business Relationship

Cipla clarified that Pharmathen serves as a supply partner, specifically manufacturing Lanreotide Injection for Cipla USA Inc., which is a wholly owned subsidiary of the company. The clarification was made under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company received communication from stock exchanges seeking clarification on media reports about the USFDA observations, prompting the formal disclosure.

Company Response and Impact Assessment

Cipla stated it is currently evaluating the impact of the USFDA observations on Pharmathen's facility. The company has committed to keeping stock exchanges informed of any updates that may have material impact, in accordance with applicable regulatory requirements.

The clarification was signed by Company Secretary Rajendra Chopra and filed with BSE Limited, National Stock Exchange of India Limited, and SOCIETE DE LA BOURSE DE Luxembourg, covering all relevant stock exchanges where Cipla securities are listed.